| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
Polysarcosine 20 does not have a classical pharmacological target but functions as a polymer excipient. Its "target" in drug delivery applications is the biological environment, where its hydrophilic and stealth properties reduce opsonization and uptake by the mononuclear phagocyte system, thereby extending circulation time. It can be conjugated to targeting ligands for active delivery to specific cells or tissues.
|
|---|---|
| ln Vitro |
In vitro, Polysarcosine 20 is evaluated for its biocompatibility, protein-repellent properties, and ability to stabilize drug formulations. It shows low cytotoxicity and minimal immunogenicity in cell culture models. As a PEG alternative, it demonstrates comparable or superior performance in reducing non-specific protein adsorption and cellular uptake, making it suitable for surface modification of nanoparticles and therapeutic proteins.
|
| ln Vivo |
In vivo, Polysarcosine 20 exhibits prolonged blood circulation compared to traditional PEG polymers due to its hydrophilic nature and reduced interaction with the immune system. It can remain in the bloodstream for extended periods, enhancing the pharmacokinetic profile of conjugated drugs. Its biocompatibility and low immunogenicity have been demonstrated in animal models, supporting its use in drug delivery applications.
|
| Enzyme Assay |
The non-cellular assay for Polysarcosine 20 involves physicochemical characterization using techniques such as gel permeation chromatography (GPC) to determine molecular weight and polydispersity, and nuclear magnetic resonance (NMR) to confirm chemical structure. Protein adsorption studies are conducted by incubating the polymer with serum proteins and measuring bound protein via SDS-PAGE or bicinchoninic acid (BCA) assay to assess its stealth properties.
|
| Cell Assay |
In vitro cell-based assays for Polysarcosine 20 involve culturing mammalian cell lines (e.g., HEK293, HeLa) in the presence of varying concentrations of the polymer. Cell viability is assessed using MTT or CellTiter-Glo assays to evaluate cytotoxicity. Cellular uptake of fluorescently labeled Polysarcosine 20 is measured by flow cytometry or fluorescence microscopy to determine its interaction with cells.
|
| Animal Protocol |
In vivo animal study protocols for Polysarcosine 20 typically involve intravenous administration to mice or rats. Pharmacokinetic studies involve collecting blood samples at various time points to measure polymer concentration using HPLC or fluorescence detection. Biodistribution studies assess tissue accumulation. Standard protocols for evaluating biocompatibility and immunogenicity are followed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Polysarcosine 20 are characterized by prolonged circulation time due to its hydrophilic nature and reduced renal clearance. With an average molecular weight of 1500, it is above the renal filtration threshold, contributing to extended half-life. The polymer is expected to be eliminated slowly, with minimal accumulation in organs. Detailed PK parameters require further characterization in specific formulations.
|
| Toxicity/Toxicokinetics |
Toxicological data for Polysarcosine 20 are limited but indicate low toxicity and good biocompatibility. As a PEG alternative, it is designed to avoid the immunogenicity and hypersensitivity reactions sometimes associated with PEG. Standard safety precautions should be observed during handling. The compound is for research use only and not approved for human therapeutic use.
|
| References | |
| Additional Infomation |
Polysarcosine 20 (pSar 20) is a hydrophilic polymer used as an alternative to PEG in drug delivery research. Its peptide backbone provides biodegradability and reduced immunogenicity. It can be used to formulate nanoparticles, polymer-drug conjugates, and protein conjugates for targeted delivery. It is not an FDA-approved drug and has no marketing authorization.
|
| Molecular Weight |
1500 (Average)
|
|---|---|
| Appearance |
Typically exists as solids at room temperature
|
| Synonyms |
pSar 20
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
